stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Current ratio
Spyre Therapeutics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 27.4×, up 14.1× from fiscal 2025 (13.3×). Over the past ten years it has ranged from 4.1× (fiscal 2019) to 16.8× (fiscal 2016); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 13.3× | 17.75% |
| FY2024 | 11.3× | 5.39% |
| FY2023 | 10.7× | 151.41% |
| FY2022 | 4.2× | (13.47%) |
| FY2021 | 4.9× | (46.11%) |
| FY2020 | 9.1× | 124.47% |
| FY2019 | 4.1× | (45.80%) |
| FY2018 | 7.5× | (23.35%) |
| FY2017 | 9.8× | (41.69%) |
| FY2016 | 16.8× | 10.40% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 27.4× | 47.84% |
| Jun 2026 | 18.5× | 106.57% |
| Mar 2026 | 9.0× | (32.32%) |
| Dec 2025 | 13.3× | 21.54% |
| 40 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. | 27.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement